ValamAi Limited today announced that Prof. Friedrich Metzger has joined its Scientific Advisory Board. Prof. Metzger co-invented VMB-100, ValamAi's engineered IGF-1 mRNA therapeutic, and previously led preclinical development of Risdiplam (Evrysdi™) at Roche, an FDA/EMA-approved oral therapy for spinal muscular atrophy. He brings more than 18 years of pharma and biotech R&D experience to ValamAi's platform and pipeline strategy.
Prof. Metzger is Co-Founder & CSO of Versameb AG, Professor of Neurobiology at the University of Freiburg, and holds a Ph.D. in Pharmacology from the University of Tübingen. He has authored more than 100 publications with over 3,700 citations across his career in RNA therapeutics and IGF-1 biology.
“Friedrich's deep expertise in RNA therapeutics and his firsthand experience bringing Risdiplam from bench to approval make him an invaluable addition to our Scientific Advisory Board,” said a ValamAi spokesperson. “His guidance will be instrumental as we advance VMB-100 through clinical development and expand into new indications.”
ValamAi Limited is a clinical-stage company based in Abu Dhabi, United Arab Emirates, focused on transforming RNA therapeutics to treat unmet medical needs. Its lead program, VMB-100, is an engineered IGF-I mRNA therapeutic in development for stress urinary incontinence and disc herniation, alongside a growing pipeline spanning dermatology and oncology.
Media Contact: info@valamai.com
